Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pilotti

Showing results (271-280 of 302) with videos related to

Pageof 31
Sort By:
Oncogene|September 19, 1996
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation testV M De Benedetti, P Radice, P Mondini, et al.
The Journal of Pathology|February 14, 2006
PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcomaM S Lagonigro, E Tamborini, T Negri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesF Grosso, R Sanfilippo, E Virdis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2014
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysisP Bossi, E Orlandi, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2012
Sunitinib malate in solitary fibrous tumor (SFT)S Stacchiotti, T Negri, M Libertini, et al.
American Journal of Obstetrics and Gynecology|August 1, 1982
Natural history of dysgerminomaG De Palo, S Pilotti, R Kenda, et al.
Targeted Oncology|July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFTM Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Oncogene|June 6, 2006
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patientsE Tamborini, S Pricl, T Negri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2013
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenicsS Stacchiotti, M Tortoreto, F Bozzi, et al.
BMC Cancer|February 8, 2017
Mechanism of action of trabectedin in desmoplastic small round cell tumor cellsS Uboldi, I Craparotta, G Colella, et al.
Pageof 31

Showing results (271-280 of 302) with videos related to

Sort By:
Pageof 31
Oncogene|September 19, 1996
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation testV M De Benedetti, P Radice, P Mondini, et al.
The Journal of Pathology|February 14, 2006
PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcomaM S Lagonigro, E Tamborini, T Negri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesF Grosso, R Sanfilippo, E Virdis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2014
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysisP Bossi, E Orlandi, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2012
Sunitinib malate in solitary fibrous tumor (SFT)S Stacchiotti, T Negri, M Libertini, et al.
American Journal of Obstetrics and Gynecology|August 1, 1982
Natural history of dysgerminomaG De Palo, S Pilotti, R Kenda, et al.
Targeted Oncology|July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFTM Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Oncogene|June 6, 2006
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patientsE Tamborini, S Pricl, T Negri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2013
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenicsS Stacchiotti, M Tortoreto, F Bozzi, et al.
BMC Cancer|February 8, 2017
Mechanism of action of trabectedin in desmoplastic small round cell tumor cellsS Uboldi, I Craparotta, G Colella, et al.
Pageof 31